Considering all of the results in this study, we propose a model in which miR-21 plays an oncogenic role by activating the PI3K/AKT/mTOR pathway and suppressing the FOXO1/Bim pathway at multiple levels in DLBCL (Fig. 4). The gene discussed is FOXO1; the disease is diffuse large B-cell lymphoma.